Opko Health, a New York-listed pharmaceutical company, has made a strategic investment of $1m in ChromaDex and acquired the rights to sell its dietary supplements in Latin America.
Opko Health, a New York-listed pharmaceutical company, has made a strategic investment of $1m in ChromaDex and acquired the rights to sell its dietary supplements in Latin America.
Opko had previously bought 13% of Fabrus’ outstanding shares in November 2010 as part of a $2.1m round.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
